Page last updated: 2024-11-04

gatifloxacin and Antibiotic-Associated Colitis

gatifloxacin has been researched along with Antibiotic-Associated Colitis in 5 studies

Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.

Research Excerpts

ExcerptRelevanceReference
"Since 2002, an epidemic of Clostridium difficile infections has occurred in southern Quebec, Canada."1.35Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. ( Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M, 2008)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hecht, DW1
Galang, MA1
Sambol, SP1
Osmolski, JR1
Johnson, S1
Gerding, DN1
Adams, DA1
Riggs, MM1
Donskey, CJ1
Labbé, AC1
Poirier, L1
Maccannell, D1
Louie, T1
Savoie, M1
Béliveau, C1
Laverdière, M1
Pépin, J1
Mohr, J1
Dhalla, IA1
Mamdani, MM1
Simor, AE1
Kopp, A1
Rochon, PA1
Juurlink, DN1

Other Studies

5 other studies available for gatifloxacin and Antibiotic-Associated Colitis

ArticleYear
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enter

2007
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8

    Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Dis

2007
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9

    Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acqu

2008
Outbreak of Clostridium difficile infection and gatifloxacin use in a long-term care facility.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Sep-15, Volume: 39, Issue:6

    Topics: Anti-Infective Agents; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; F

2004
Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?
    Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:9

    Topics: Aged; Aged, 80 and over; Aza Compounds; Case-Control Studies; Clostridioides difficile; Enterocoliti

2006